Kenvue (US:KVUE) Benzingaยท2025-09-05 18:48Core Viewpoint - A report by Health Secretary Robert F. Kennedy Jr. is expected to suggest a link between the use of acetaminophen (Tylenol) during pregnancy and an increased risk of autism, impacting Kenvue's stock performance [1][5]. Group 1: Report Findings - The upcoming report from the Department of Health and Human Services (HHS) will likely highlight insufficient folate levels and prenatal exposure to acetaminophen as potential contributing factors to autism [2]. - Research mentioned in the report indicates that a specific form of folate, folinic acid (leucovorin), may help alleviate autism-related symptoms [3]. - The report is anticipated to be published this month, with a focus on the implications of acetaminophen use during pregnancy [2]. Group 2: Company Response - Following the news of the HHS findings, Kenvue's stock dropped approximately 14% [5]. - A spokesperson for Kenvue stated that the company prioritizes patient safety and maintains that there is no proven causal relationship between acetaminophen use in pregnancy and autism [6]. - Kenvue emphasizes its commitment to continuously evaluate scientific evidence regarding the safety of its products [6]. Group 3: Industry Context - The American College of Obstetricians and Gynecologists currently considers acetaminophen safe for use during pregnancy, advising that it should be taken under medical guidance [4]. - The HHS is also set to announce new federal grants to support autism research as part of the National Institutes of Health's broader data science program [7].